10x Genomics (TXG) Equity Ratio (2018 - 2026)

10x Genomics has disclosed Equity Ratio across 9 years of filings, most recently posting 0.8 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.8, up 2.45% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.8 (up 2.45% YoY), and the FY2025 annual result was 0.76, down 1.08% from the prior year.
• Equity Ratio came in at 0.8 for Q1 2026 at 10x Genomics, up from 0.76 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.8 in Q1 2022 to a low of 0.76 in Q3 2025.
• The 5-year median for Equity Ratio is 0.78 (2022), against an average of 0.78.
• Across the five-year window, Equity Ratio fell 3.6% in 2022 and increased 2.47% in 2023, its largest moves.
• 10x Genomics' Equity Ratio stood at 0.78 in 2022, then dropped by 1.95% to 0.77 in 2023, then increased by 0.68% to 0.77 in 2024, then fell by 1.08% to 0.76 in 2025, then rose by 4.84% to 0.8 in 2026.
• The last three Equity Ratio figures came in at 0.8 (Q1 2026), 0.76 (Q4 2025), and 0.76 (Q3 2025), per Business Quant data.